Biomedical Renaissance, LLC -- A New and Timely Business Venture

Dr. David Harder, Professor and Director of the Cardiovascular Center at the Medical College of Wisconsin (MCW), in conjunction with Paul and Lon Frederick of Frederick & Company, Inc., have established a consulting firm -- Biomedical Renaissance, LLC.

Dr. Harder is Editor-In-Chief of The American Journal of Physiology: Heart & Circulatory Physiology and consults internationally for a variety of business, academic, and government interests. He will have direct responsibility for both the scientific oversight of the consulting program, as well as the selection of the consulting team. Dr. David Gutterman, holder of the Northwestern Mutual Endowed Chair for Investigative Cardiology and Professor and Vice Chairman of the Department of Medicine at MCW, will assist Dr. Harder in selecting a group of recognized experts representing a diverse array of medical and biomedical applications from organizations within North America and Europe. It is anticipated that a number of consultants will be faculty members of MCW. Additionally, Biomedical Renaissance intends to provide consulting services for new veterinary therapies and drugs. Accordingly, Dr. Randy Schuett, currently President of the Wisconsin Veterinary Association, will be a consultant for the company.

The intent of Biomedical Renaissance is to offer expert consulting opinions and advice, along with unbiased factual reports on biomedical issues, problems, products, and new potentials of existing pharmaceuticals. It will provide new genetic based strategies in medical and biomedical applications unrelated to direct interests or discoveries of the company, its officers, consultants or employees. In the course of consultation, the company may pursue joint ventures involving proprietary opinions, techniques or services.

Paul and Lon Frederick are Chairman and President respectively of Frederick & Company, Inc., an investment-banking firm formed in 1960. They will be responsible for coordinating business and corporate initiatives, bringing a wealth of experience providing financial assistance and advice to selective emerging growth companies.

The target audience for Biomedical Renaissance is expected to be varied, ranging from angel investment groups to academic and government institutions requiring a knowledgeable, state-of-the-art assessment of new biomedical products, pharmaceuticals, chemical reagents, and medical devices for new treatments and market place potential. The rapidly emerging field of genetic therapy will need critical evaluation as new genetic tests targeting genes related to disease are established and subsequent genetic therapies are commercialized. The majority of consultants used by Biomedical Renaissance will be scientists employed by top ranked academic institutions and/or highly-respected academic clinicians experienced in using basic research in clinical practice. This will allow Biomedical Renaissance to serve as "a think tank" for academic, governmental and pharmaceutical institutions providing ideas for new therapies and biochemical reagents and in evaluating new drugs, chemical and biomedical devices.